Iovance Biotherapeutics, Inc.

General ticker "IOVA" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $2.3B (TTM average)

Iovance Biotherapeutics, Inc. follows the US Stock Market performance with the rate: 11.2%.

Estimated limits based on current volatility of 14.4%: low 2.25$, high 3.01$

Factors to consider:

  • US accounted for 98.2% of revenue in the fiscal year ended 2024-12-31
  • Current price 56.9% below estimated low

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [4.06$, 10.16$]
  • 2025-12-31 to 2026-12-31 estimated range: [2.51$, 6.75$]

Financial Metrics affecting the IOVA estimates:

  • Negative: Non-GAAP EPS, $ of -1.30 <= 0.04
  • Positive: -0.87 < Investing cash flow per share, $ of -0.33
  • Negative: negative Operating income
  • Negative: negative Net income
  • Negative: Operating cash flow per share per price, % of -12.82 <= 1.79
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Positive: Interest expense per share, $ of 0 <= 0
  • Positive: Inventory ratio change, % of -65.82 <= -1.01

Similar symbols

Short-term IOVA quotes

2025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-252025-04-282025-04-292025-04-302025-05-012025-05-022025-05-052025-05-062025-05-072025-05-082025-05-0922.533.5
Price $

Long-term IOVA plot with estimates

24681012141618Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026Jan 2027−0.4−0.3−0.2−0.10
IOVAS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $0.00MM $1.19MM $164.07MM
Operating Expenses $398.88MM $461.75MM $559.35MM
Operating Income $-398.88MM $-460.56MM $-395.28MM
Non-Operating Income $2.98MM $13.04MM $20.27MM
R&D Expense $294.78MM $344.08MM $282.34MM
Income(Loss) $-395.89MM $-447.52MM $-375.00MM
Taxes $0.00MM $-3.48MM $-2.83MM
Profit(Loss)* $-389.92MM $-444.04MM $-372.18MM
Stockholders Equity $499.64MM $584.61MM $710.40MM
Inventory $0.00MM $10.37MM $51.52MM
Assets $663.98MM $780.35MM $910.43MM
Operating Cash Flow $-292.76MM $-361.82MM $-352.98MM
Capital expenditure $20.43MM $22.29MM $11.07MM
Investing Cash Flow $256.45MM $-155.24MM $-96.41MM
Financing Cash Flow $190.15MM $462.96MM $390.66MM
Earnings Per Share** $-2.45 $-1.89 $-1.28

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.